IASO Bio acquires MediSix Therapeutics to expand global cell therapy platform
- nuaxia
- il y a 15 minutes
- 3 min de lecture
The completed acquisition adds MediSix’s PEBL T-cell engineering technology, clinical pipeline and Singapore-based R&D team to IASO Bio’s existing cell therapy development, manufacturing and commercial capabilities.
IASO Biotechnology has completed the acquisition of Singapore-based MediSix Therapeutics, adding its proprietary T-cell engineering platform, development pipeline and international research team to IASO Bio’s cell therapy organisation; financial terms were not disclosed.
The transaction broadens IASO Bio’s technology and pipeline capabilities in T-cell malignancies and other diseases while establishing Singapore as an additional component of its international cell therapy development network.
Field | Content |
Alert Type | Deal |
Companies | IASO Biotechnology (IASO Bio); MediSix Therapeutics |
Deal Type | Acquisition |
Asset or Company | MediSix Therapeutics, including its PEBL (Protein Expression Blocker) platform, pipeline and R&D capabilities |
Therapy Area(s) | Haematological malignancies; Oncology; Autoimmune diseases |
Technology or Modality | CAR-T cell therapy; T-cell engineering; PEBL technology; ex vivo and in vivo CAR-T approaches |
Deal Value | Financial terms were not disclosed. |
Development Stage | Clinical and research stage; lead programme IASO107 (formerly PCART7) is undergoing clinical evaluation. (PR Newswire) |
Geography | Singapore; China; global |
What Happened | On 13 August 2026, IASO Bio announced that it had completed its acquisition of MediSix Therapeutics, a Singapore-based immune cell engineering and cell therapy company. IASO gains MediSix’s proprietary PEBL platform, R&D pipeline and international team. MediSix’s lead programme, IASO107, formerly PCART7, is undergoing clinical evaluation. MediSix will continue developing follow-on products from its platform while using IASO Bio’s CMC, clinical-development, manufacturing and commercial capabilities. Financial terms were not disclosed. (PR Newswire) |
Why It Matters | The acquisition adds a differentiated T-cell engineering technology to IASO Bio’s existing cell therapy platform. MediSix’s PEBL approach is designed to suppress selected target proteins on T-cell surfaces, reducing CAR-T cell fratricide and enabling development against antigens shared by therapeutic T cells and malignant T cells — a significant technical challenge in developing cell therapies for T-cell malignancies. (PR Newswire) |
Supporting Context | MediSix was founded in Singapore in 2016 based on research by CAR-T pioneer Professor Dario Campana. Its PEBL platform has been applied to programmes including IASO107/PCART7, a CD7-directed approach developed for T-cell malignancies, while IASO Bio already operates an integrated cell therapy business spanning discovery, development, manufacturing and commercialisation. (PR Newswire) |
Strategic Rationale | IASO Bio gains MediSix’s technology, clinical programmes and Singapore-based talent and research infrastructure, complementing its existing CMC and cell therapy development capabilities. MediSix’s programmes gain access to IASO Bio’s established manufacturing, clinical-development and commercial infrastructure, which the companies intend to use to support international development. (PR Newswire) |
Potential Impact | Integration of the PEBL platform could broaden IASO Bio’s pipeline into additional T-cell malignancies and other diseases where conventional CAR-T engineering faces target-related challenges. Any clinical impact will depend on the performance of IASO107 and subsequent programmes in prospective clinical development. |
Key Takeaway | The completed MediSix acquisition gives IASO Bio a specialist T-cell engineering platform and Singapore R&D presence as it expands its cell therapy pipeline internationally. |
What to Watch | Clinical progress for IASO107, development of follow-on programmes using the PEBL platform and how IASO Bio integrates MediSix’s Singapore operations into its broader international R&D and manufacturing network. |
Primary Source | |
Relevant Date | 13 August 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Commentaires